Loading quotes...

Forecast

There is no analyst data available for this company.

Discussions in the community

There is no discussion about this asset yet.

Start discussion

News Go to news feed

AddLife reports stable Q1-2026 results and stock jumps sharply

AddLife recorded a 2% decline in net sales in the first quarter of 2026 due to currency effects and divestments, while organic growth adjusted was 3%. The EBITDA margin remained robust at 12.5% and profit before tax rose by 7%. Management emphasized a strategic focus on advanced products and acquisitions to boost margins. After the figures, the share price climbed 20.71% to 144.25, driven by positive investor reaction and an improved EPS outlook. » More on de.investing.com
AddLife misses revenue forecasts in first quarter

AddLife reported net sales of SEK 2.65 billion for the first quarter, below analysts’ expectation of SEK 2.74 billion; sales thus fell by 2%. Earnings per share were SEK 1.04, net profit SEK 128 million and EBITA SEK 332 million with an EBITA margin of 12.5%. Currency effects reduced revenue and EBITA by 4% each, organic growth was 3% and acquisition-driven growth 2%. During the quarter AddLife completed two acquisitions in the UK and Austria, but divestments and negative currency effects weighed on total sales. » More on de.investing.com
AddLife raises margins and reduces debt – shares jump 23%

AddLife reports a currency-adjusted revenue increase of 2% for Q4 2025 despite negative currency effects and a slightly improved EBITA margin of 12.4%. Operating cash-flow growth was strong (SEK 1,392 million), net debt fell by SEK 773 million and the net debt/EBITDA ratio is now 2.2. Two acquisitions (Pharmacold, Opitek) were completed at multiples below 7x EV/EBITDA; management is targeting roughly 15% earnings growth for 2026. » More on de.investing.com
AddLife records strong EBITDA growth in Q4 2025, shares climb over 23%

AddLife reported adjusted EBITDA growth of 5% for Q4 2025 and improved the full‑year EBITDA margin to 12.1% (from 10.5% in 2023). Despite negative currency effects that reduced revenue by 5% and EBITDA by 7%, operating cash flow in the quarter rose to SEK 900 million and annual cash flow reached SEK 1.4 billion. The share price jumped 23.22% to SEK 147.25; management plans multiple acquisitions in 2026 and targets 15% profit growth for 2026. Net debt stands at 2.2x EBITDA with a goal to remain below 3x. » More on de.investing.com
AddLife Registered B expects increase in revenue and profit in quarterly report

AddLife Registered B is expected to release its figures for the quarter ending June 30, 2025, on July 15, 2025. Analysts forecast a significant rise in earnings per share and a slight increase in revenue compared to the same quarter last year. Higher profits and revenues are also anticipated for the current fiscal year. » More on finanzen.net

Historical dividends Dividends

All dividend metrics All metrics

In 2026, AddLife B has already paid €0.14 in dividends. The last payout was in May.

Financials

In the last quarter, AddLife B had revenue of €229.24m and net profit of €11.2m

(EUR)	September 2026	YoY
Revenue	229.24m	4.32%
Gross profit	88.11m	7.26%
Net profit	11.2m	52.86%
EBITDA	34.49m	4.73%

Fundamentals

Metric	Value
Market capitalization	€1.93bn
Number of shares	117.29m
52-week high/low	€17.31 - €11.98
Dividend yield	0.84%
Dividends TTM	€0.14
Beta	1.57
P/E ratio	34.62
PEG ratio	0.55
P/B ratio	3.73
P/S ratio	2.00

Company profile

AddLife AB (publ), together with its subsidiaries, provides equipment, medical devices, and reagents primarily to healthcare system, research, colleges, and universities, as well as the food and pharmaceutical industries. The company operates in two segments, Labtech and Medtech. The Labtech segment offers products, solutions, and services in the areas of diagnostics, and biomedical research and laboratory equipment for haematology, pathology, point-of-care diagnostics, cell biology, genetics, microbiology, virology, molecular biology, clinical chemistry, immunology, consumables, and analytical instruments segments. This segment also offers support, maintenance, advice, and training services. The Medtech segment provides medical device products for surgery, respiration, intensive care, wound care, enteral nutrition, fall prevention, welfare technology, ear, and nose and throat segments, as well as bathroom-related assistive devices and assistive devices for children with disabilities. It operates in Sweden, Finland, Denmark, Norway, the United Kingdom, Ireland, Germany, Italy, Austria, Switzerland, rest of Europe, and internationally. AddLife AB (publ) was founded in 1906 and is based in Stockholm, Sweden.